Third, given that we did not find any group differences on SERT-related FC, ourfindings suggest that drugs specifically targeting the SERT (i.e. selectiveserotonin reuptake inhibitors SSRIs) are unlikely to offer any promise in addressingprimary fatigue in multiple sclerosis. This evidence concerns the gene SLC6A4 and multiple sclerosis.